Literature DB >> 22159221

Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.

Shihua Wang1, Jiansheng Wu, Janel Suburu, Zhennan Gu, Jiaozhong Cai, Linara S Axanova, Scott D Cramer, Michael J Thomas, Donna L Perry, Iris J Edwards, Lorelei A Mucci, Jennifer A Sinnott, Massimo F Loda, Guangchao Sui, Isabelle M Berquin, Yong Q Chen.   

Abstract

A common treatment of advanced prostate cancer involves the deprivation of androgens. Despite the initial response to hormonal therapy, eventually all the patients relapse. In the present study, we sought to determine whether dietary polyunsaturated fatty acid (PUFA) affects the development of castration-resistant prostate cancer. Cell culture, patient tissue microarray, allograft, xenograft, prostate-specific Pten knockout and omega-3 desaturase transgenic mouse models in conjunction with dietary manipulation, gene knockdown and knockout approaches were used to determine the effect of dietary PUFA on castration-resistant Pten-null prostate cancer. We found that deletion of Pten increased androgen receptor (AR) expression and Pten-null prostate cells were castration resistant. Omega-3 PUFA slowed down the growth of castration-resistant tumors as compared with omega-6 PUFA. Omega-3 PUFA decreased AR protein to a similar extent in tumor cell cytosolic and nuclear fractions but had no effect on AR messenger RNA level. Omega-3 PUFA treatment appeared to accelerate AR protein degradation, which could be blocked by proteasome inhibitor MG132. Knockdown of AR significantly slowed down prostate cancer cell proliferation in the absence of androgens. Our data suggest that omega-3 PUFA inhibits castration-resistant prostate cancer in part by accelerating proteasome-dependent degradation of the AR protein. Dietary omega-3 PUFA supplementation in conjunction with androgen ablation may significantly delay the development of castration-resistant prostate cancer in patients compared with androgen ablation alone.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22159221      PMCID: PMC3271270          DOI: 10.1093/carcin/bgr290

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  37 in total

Review 1.  Pten inactivation and the emergence of androgen-independent prostate cancer.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

2.  Ratio of n-6 to n-3 fatty acids and bone mineral density in older adults: the Rancho Bernardo Study.

Authors:  Lauren A Weiss; Elizabeth Barrett-Connor; Denise von Mühlen
Journal:  Am J Clin Nutr       Date:  2005-04       Impact factor: 7.045

3.  Culture of mouse prostatic epithelial cells from genetically engineered mice.

Authors:  Wendy W Barclay; Scott D Cramer
Journal:  Prostate       Date:  2005-05-15       Impact factor: 4.104

4.  Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.

Authors:  M E McMenamin; P Soung; S Perera; I Kaplan; M Loda; W R Sellers
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

5.  Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.

Authors:  Jing Jiao; Shunyou Wang; Rong Qiao; Igor Vivanco; Philip A Watson; Charles L Sawyers; Hong Wu
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

6.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Authors:  M A Eisenberger; B A Blumenstein; E D Crawford; G Miller; D G McLeod; P J Loehrer; G Wilding; K Sears; D J Culkin; I M Thompson; A J Bueschen; B A Lowe
Journal:  N Engl J Med       Date:  1998-10-08       Impact factor: 91.245

7.  Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.

Authors:  R J Vlietstra; D C van Alewijk; K G Hermans; G J van Steenbrugge; J Trapman
Journal:  Cancer Res       Date:  1998-07-01       Impact factor: 12.701

8.  Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids.

Authors:  Isabelle M Berquin; Younong Min; Ruping Wu; Jiansheng Wu; Donna Perry; J Mark Cline; Mike J Thomas; Todd Thornburg; George Kulik; Adrienne Smith; Iris J Edwards; Ralph D'Agostino; Hao Zhang; Hong Wu; Jing X Kang; Yong Q Chen
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

Review 9.  Dietary fat-gene interactions in cancer.

Authors:  Yong Q Chen; Iris J Edwards; Steven J Kridel; Todd Thornburg; Isabelle M Berquin
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

10.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

Authors:  M Yoshimoto; I W Cunha; R A Coudry; F P Fonseca; C H Torres; F A Soares; J A Squire
Journal:  Br J Cancer       Date:  2007-08-14       Impact factor: 7.640

View more
  23 in total

1.  Differential tumorigenic potential and matriptase activation between PDGF B versus PDGF D in prostate cancer.

Authors:  Abdo J Najy; Joshua J Won; Lisa S Movilla; Hyeong-Reh C Kim
Journal:  Mol Cancer Res       Date:  2012-06-11       Impact factor: 5.852

2.  A critical role of the PTEN/PDGF signaling network for the regulation of radiosensitivity in adenocarcinoma of the prostate.

Authors:  Michael Christensen; Abdo J Najy; Michael Snyder; Lisa S Movilla; Hyeong-Reh Choi Kim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-01-01       Impact factor: 7.038

3.  Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.

Authors:  Nanmeng Yu; Shelby Puckett; Peter A Antinozzi; Scott D Cramer; Douglas S Lyles
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

4.  Omega-3 fatty acids and other FFA4 agonists inhibit growth factor signaling in human prostate cancer cells.

Authors:  Ze Liu; Mandi M Hopkins; Zhihong Zhang; Chrystal B Quisenberry; Louise C Fix; Brianna M Galvan; Kathryn E Meier
Journal:  J Pharmacol Exp Ther       Date:  2014-12-09       Impact factor: 4.030

5.  The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma.

Authors:  Peter Paximadis; Abdo J Najy; Michael Snyder; Hyeong-Reh Kim
Journal:  Prostate       Date:  2016-01-06       Impact factor: 4.104

Review 6.  Roles of endogenous ether lipids and associated PUFAs in the regulation of ion channels and their relevance for disease.

Authors:  Delphine Fontaine; Sandy Figiel; Romain Félix; Sana Kouba; Gaëlle Fromont; Karine Mahéo; Marie Potier-Cartereau; Aurélie Chantôme; Christophe Vandier
Journal:  J Lipid Res       Date:  2020-04-07       Impact factor: 5.922

Review 7.  Immune regulation and anti-cancer activity by lipid inflammatory mediators.

Authors:  Saraswoti Khadge; John Graham Sharp; Timothy R McGuire; Geoffrey M Thiele; Paul Black; Concetta DiRusso; Leah Cook; Lynell W Klassen; James E Talmadge
Journal:  Int Immunopharmacol       Date:  2018-11-14       Impact factor: 4.932

Review 8.  The role of free-fatty acid receptor-4 (FFA4) in human cancers and cancer cell lines.

Authors:  Ilya S Senatorov; Nader H Moniri
Journal:  Biochem Pharmacol       Date:  2018-02-13       Impact factor: 5.858

9.  n-3 Polyunsaturated Fatty Acids and their Role in Cancer Chemoprevention.

Authors:  Zhennan Gu; Kai Shan; Haiqin Chen; Yong Q Chen
Journal:  Curr Pharmacol Rep       Date:  2015-07-05

Review 10.  The fat side of prostate cancer.

Authors:  Giorgia Zadra; Cornelia Photopoulos; Massimo Loda
Journal:  Biochim Biophys Acta       Date:  2013-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.